share_log

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

隨着每股收益的增長及更多,3sBio(HKG: 1530)提出了一個有趣的案例
Simply Wall St ·  2023/08/12 20:29

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.

對一些投機者來說,投資一家能夠扭轉命運的公司的興奮感是一個很大的吸引力,因此,即使是沒有收入、沒有利潤、有虧損記錄的公司,也可以設法找到投資者。不幸的是,這些高風險投資通常幾乎不可能獲得回報,許多投資者爲吸取教訓付出了代價。虧損的公司尚未用利潤證明自己,最終外部資本的流入可能會枯竭。

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like 3SBio (HKG:1530). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

因此,如果這種高風險和高回報的想法不適合,你可能會對盈利的成長型公司更感興趣,比如 3sBio (HKG: 1530)。現在,這並不是說該公司提供了最好的投資機會,但盈利能力是商業成功的關鍵組成部分。

See our latest analysis for 3SBio

查看我們對 3sBio 的最新分析

How Fast Is 3SBio Growing?

3sBio 的增長速度有多快?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Shareholders will be happy to know that 3SBio's EPS has grown 28% each year, compound, over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.

如果你認爲市場的效率甚至隱約可觀,那麼從長遠來看,你預計公司的股價將跟隨其每股收益(EPS)的結果。因此,有經驗的投資者在進行投資研究時密切關注公司的每股收益是有道理的。股東們會很高興得知,在三年中,3sBio的每股收益每年複合增長28%。通常,如果一家公司能跟上步伐,我們會這樣說 那個 有點像增長,股東們會喜氣洋洋。

Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. EBIT margins for 3SBio remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 7.5% to CN¥6.9b. That's progress.

收入增長是增長可持續的重要指標,再加上高利息和稅前收益(EBIT)利潤率,這是公司在市場上保持競爭優勢的好方法。去年,3sBio的息稅前利潤率基本保持不變,但該公司應該很高興地報告其在此期間的收入增長了7.5%,達到69億人民幣。這就是進步。

The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.

下圖顯示了該公司的收入和收入隨着時間的推移是如何發展的。點擊圖表查看確切的數字。

earnings-and-revenue-history
SEHK:1530 Earnings and Revenue History August 13th 2023
聯交所:1530 2023 年 8 月 13 日收益及收入記錄

You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for 3SBio's future profits.

你開車時不會盯着後視鏡,所以你可能會對此更感興趣 免費的 報告顯示了分析師對3sBio的預測 將來 利潤。

Are 3SBio Insiders Aligned With All Shareholders?

3sBio Insiders 是否與所有股東保持一致?

It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. 3SBio followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. Indeed, they have a considerable amount of wealth invested in it, currently valued at CN¥1.1b. This suggests that leadership will be very mindful of shareholders' interests when making decisions!

公司領導者必須爲股東的最大利益行事,因此內幕投資總是讓市場放心。3sBio的追隨者知道內部人士擁有大量資金,可以與更廣泛的股東羣體保持一致,他們會感到安慰。事實上,他們有大量的財富投資於此,目前價值爲11億人民幣。這表明領導層在做出決策時會非常注意股東的利益!

Does 3SBio Deserve A Spot On Your Watchlist?

3sBio 值得在你的關注名單上佔有一席之地嗎?

If you believe that share price follows earnings per share you should definitely be delving further into 3SBio's strong EPS growth. This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares. The growth and insider confidence is looked upon well and so it's worthwhile to investigate further with a view to discern the stock's true value. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if 3SBio is trading on a high P/E or a low P/E, relative to its industry.

如果你認爲股價跟隨每股收益,那麼你絕對應該進一步研究3sBio的強勁每股收益增長。這種每股收益的增長率是該公司應該爲之驕傲的,因此,內部人士持有相當一部分股票也就不足爲奇了。增長和內部信心得到了很好的關注,因此值得進一步調查,以期辨別該股的真實價值。雖然我們已經研究了收益的質量,但我們還沒有做任何工作來估值該股。因此,如果你想低價購買,你可能需要檢查一下3sBio相對於其行業的市盈率高還是低市盈率。

Although 3SBio certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see insider buying, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

儘管3sBio看起來確實不錯,但如果內部人士購買股票,它可能會吸引更多的投資者。如果你想看到內幕買盤,那麼這個 免費的 內部人士正在收購的成長型公司名單可能正是你想要的。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

請注意,本文中討論的內幕交易是指相關司法管轄區內應報告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?擔心內容嗎? 取得聯繫 直接和我們在一起。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。 我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。 它不構成買入或賣出任何股票的建議,也沒有考慮您的目標或財務狀況。我們的目標是爲您提供由基本面數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。簡而言之,華爾街在上述任何股票中都沒有頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論